Who
Neil Harris Cohen
Director
Company insider
Files Form 4 as: interim CEO, Chemomab Therapeutics.
In numbers
- Trades disclosed
- 42
- Buys
- 4
- Sells
- 3
- Bought
- $147K
- Sold
- $18K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Jul 2020
- Last trade
- 28 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Aug 2026filed 1 Sep 2026 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,8001,000 at $2.80 | filing |
| 28 Aug 2026filed 1 Sep 2026 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,8001,000 at $2.80 | filing |
| 27 Aug 2026filed 1 Sep 2026 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,7161,304 at $2.85 | filing |
| 27 Aug 2026filed 1 Sep 2026 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,7161,304 at $2.85 | filing |
| 16 Mar 2026filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,172 at $0.00 | filing |
| 16 Mar 2026filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,172 at $0.00 | filing |
| 16 Mar 2025filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,821 at $0.00 | filing |
| 16 Mar 2025filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,821 at $0.00 | filing |
| 18 Mar 2024filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,520 at $0.00 | filing |
| 18 Mar 2024filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,520 at $0.00 | filing |
| 21 Mar 2023filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,714 at $0.00 | filing |
| 21 Mar 2023filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,714 at $0.00 | filing |
| 16 Mar 2023filed 23 Mar 2023 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,875 at $0.00 | filing |
| 16 Nov 2022filed 18 Nov 2022 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,8182,409 at $2.00 | filing |
| 18 May 2022filed 19 May 2022 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,3802,000 at $3.19 | filing |
| 14 Mar 2022filed 15 Mar 2022 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,4002,000 at $4.20 | filing |
| 14 Mar 2022filed 15 Mar 2022 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,6002,000 at $4.30 | filing |
| 14 Mar 2022filed 15 Mar 2022 | CMMB Chemomab TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,1202,000 at $4.56 | filing |
| 7 Mar 2022filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,705 at $0.00 | filing |
| 7 Mar 2022filed 1 Sep 2026 | CMMB Chemomab Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,705 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.